Biomarkers, Congenital Heart Disease, Electroencephalography, Near-Infrared Spectroscopy, Neurodevelopmental Disorders
Conditions
Keywords
Congenital heart disease, Neurodevelopment, Neuromonitoring, Biomarkers, EEG, NIRS
Brief summary
Infants with congenital heart disease (CHD) are at increased risk for delayed neurodevelopment. Multiple etiological explanations have been proposed, as there seems to be a multifactorial interplay of both prenatal and perioperative factors. The main goal of this research project is to focus on peri-operative physiological risk factors in infants with CHD which impair functional brain maturation or elicit brain injury, and subsequently creating a risk model and guidelines for standardized developmental follow-up in this population. PART 1: investigation of cerebral autoregulation and neurovascular coupling The homeostasis in cerebral blood supply regardless of perfusion pressure, is called Cerebral autoregulation (CAR). Neurovascular coupling (NVC) is the phenomenon in which blood supply increases as a result of increased brain activity in a specific area. At different times in the perioperative phase, these regulatory mechanisms will be estimated based on Electroencephalography (EEG) and Near Infrared Spectroscopy (NIRS), in addition to hemodynamic parameters. PART 2: cell-free DNA (cfDNA) extraction. Non-invasive monitoring of neuronal degeneration can be performed using cfDNA extraction techniques. Serial measurements of neuronal cfDNA will be used to determine whether and when this neuronal damage has occurred. PART 3: Prognosis and outcome. These risk factors, supplemented with demographic factors and medications administered, will be combined in an Artificial Intelligence-driven model, thus establishing a risk model for neurodevelopmental outcome. This model will be compared to the current standard-of-care, both structural imaging (ultrasound and MRI) and a clinical developmental assessment at 9 and 24 months of age (Bayley Scales of Infant Development-III).
Interventions
DIAGNOSTIC_TESTelectroencephalography
Pre-, per- and postoperative electroencephalography
DIAGNOSTIC_TESTNear-Infrared Spectroscopy
Pre-, Per- and Postoperative near-infrared spectroscopy returning regional cerebral oxygen saturation
DIAGNOSTIC_TESTneuronal cell-free DNA
CfDNA which is characterized based on methylation patterns to determine the tissue of origin
Sponsors
Universitaire Ziekenhuizen KU Leuven
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 6 Months
Healthy volunteers
No
Inclusion criteria
* CHD warranting a first percutaneous or surgical intervention in the first 6 months, including but not limited to transposition of the great arteries (TGA), univentricular heart (UVH), Tetralogy of Fallot (TOF), coarctation of the aorta (CoA), total abnormal pulmonary venous drainage (TAPVU), Common arterial trunc (TA), large patent ductus arteriosus (PDA) or VSD and AVSD for which treatment is necessary within the first 6 months of life. * Treatment provided at the University Hospitals Leuven.
Exclusion criteria
* Syndromes or proven genetic conditions which are associated with neurological impairment * CHD warranting treatment after 6 months of life * Suspected or proven metabolic diseases * No parental/guardian consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical neurological development measured with Bayley Scale of Infant Development | 9 months, 24 months | Rate of abnormal clinical neurodevelopment measured with the Bayley Scale of Infant Development (BSID-III): range 50-150, mean 100, SD 15 |
| Brain MRI structural brain abnormalities | +- 1 week postoperative | Incidence of patients with normal brain development vs rate of bleeding/stroke visualized on brain MRI Differences in total brain volume and cerebellar volume in patients with congenital heart disease |
Countries
Belgium
Contacts
Primary ContactLiselotte Van Loo, MD
Outcome results
None listed